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1. Introduction 
Molecular imaging has recently been defined by the Society of Nuclear Medicine as ‘the 
visualization, characterization, and measurement of biological processes at the molecular 
and cellular levels in humans and other living systems’ (Mankoff 2007). It usually exploits 
specific labeled molecular probes, as well as intrinsic tissue characteristics as the source of 
image contrast, and uses a number of molecular imaging modalities, including magnetic 
resonance imaging, optical imaging, targeted ultrasound, single photon emission 
tomography and positron emission tomography (Massoud and Gambhir 2003). 
Angiogenesis is the development of new vasculature from pre-existing blood vessels and/or 
circulating endothelial calls (Bergers and Benjamin 2003). It is well established that 
angiogenesis is one of the key aspects in the growth and metastasis of solid tumors 
(Folkman 1995; Ferrara and Kerbel 2005). Typically tumor-associated angiogenesis goes 
through two phases, an avascular and a vascular phase that are separated by the ‘angiogenic 
switch’. The avascular phase of tumors corresponds to small and occult lesions that stay 
dormant and subsist on diffusion of nutrients from the host microvasculature. After 
reaching a certain size (usually around 1-2mm), a small subset of dormant tumors enter the 
vascular phase in which exponential tumor growth ensues. Angiogenesis is a complex 
multistep process regulated by many factors. At the onset of angiogenesis, a number of pro-
angiogenic growth factors (e.g. vascular endothelial growth factors, platelet derived growth 
factor, fibroblast growth factors) and proteolytic enzymes (e.g. metalloproteinases, cathepsin 
cysteine proteases, plasmin) are secreted into the interstitium. This leads to degradation of 
basal membrane surrounding the pre-existing vasculature, along with proliferation and 
migration of smooth muscle and endothelial cells. All these events lead to the alignment and 
organization of endothelial cells to form new vessels and a vascular network within the 
tumor (Ferrara and Kerbel 2005).  
Tumor angiogenesis is not simply the production of an increased number of blood vessels to 
serve a growing mass. Although the main purpose of tumor angiogenesis can be considered 
to maintain a cancer’s blood supply, the process occurs in an unmitigated fashion, and the 
resultant vascular network is highly abnormal. This profoundly aberrant vasculature 
dramatically alters the tumor microenvironment and influences heavily the ways in which 
cancers grow and progress, escape the host’s immune system, metastasize, and respond to 
anticancer therapies. 
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The heterogeneity in vessel distribution and haphazard anatomical arrangement of the 
vasculature cause spatial and temporal heterogeneity in blood flow, with areas of 
hypervasularity adjacent to hypovascular ones (Tong, Boucher et al. 2004). Also, the 
structural abnormalities of the tumor vasculature lead to a marked increase in vessel 
leakiness. As a consequence, there is a protein and fluid build-up in the tumor interstitium. 
This excess extravasation of protein increases the extravascular oncotic pressure, dragging 
further fluid into the interstitial space (Stohrer, Boucher et al. 2000; Tong, Boucher et al. 
2004). Furthermore, there is an absence of functional intratumoral lymphatic vessels, 
resulting in the impaired clearance of extracellular fluid and hence interstitial hypertension 
within tumors. The raised intratumoral interstitial fluid pressure (IFP) reduces the 
hydrostatic pressure gradient between the intravascular and extravascular compartments 
such that the two essentially equilibrate, which reduces transvascular flow. Also, the 
mechanical stress from the solid mass of proliferating cancer cells and the matrix is able to 
collapse tumor vessels, closing the lumen through compressive forces (Padera, Stoll et al. 
2004). This combination of regional poor perfusion, raised IFP, and areas of vascular 
collapse produces regional hypoxia and acidosis within tumors (Helmlinger, Yuan et al. 
1997). Aberrations in the tumor vasculature have great implications for tumor sensitivity to 
therapy. Hypoxia is a well-known mediator of cancer cell resistance to conventional 
radiotherapy and cytotoxics (Teicher 1996; Wouters and Brown 1997). Moreover, the poor 
blood supply and raised intratumoral IFP (leading to a reduction in transvacular flow) 
impair the delivery of systemically administered therapies to tumors such as conventional 
cytotoxics and monoclonal antibodies (Jain 1989; Tong, Boucher et al. 2004). 
With the discovery of vascular endothelial growth factor (VEGF) as a major driver of tumor 
angiogenesis, efforts were focused on novel therapeutics aimed at inhibiting VEGF activity, 
with the goal of regressing tumors by starvation. Unfortunately, clinical trials of anti-VEGF 
monotherapy in patients with solid tumors have been largely negative (Jain, Duda et al. 
2006). Intriguingly, the combination of anti-VEGF therapy with conventional chemotherapy 
has improved survival in cancer patients compared with chemotherapy alone (Sandler, Gray 
et al. 2006; Saltz, Clarke et al. 2008). In 2001, a ‘vascular normalization’ hypothesis was 
proposed to explain this paradox (Jain 2001). The normalization hypothesis suggests that by 
correcting the abnormalities in structure and function of tumor vessels (rather than 
destroying vessels completely) we can normalize the tumor microenvironment and 
ultimately control tumor progression and improve response to other therapies (Jain 2005). 
Non-invasive imaging of tumor angiogenesis will allow for much earlier detection of tumors 
and also the development of surrogate markers for assessing response to treatment.  
2. Imaging of angiogenesis 
Imaging angiogenesis has been focused into three different arenas: 1) kinetic imaging using 
dynamic tracking of contrast administration; 2) steady state blood volume determinations of 
neovascular density; and 3) specific molecular markers of angiogenesis. 
2.1 Kinetic imaging using dynamic tracking of contrast material 
Dynamic contrast-enhanced imaging is a noninvasive technique that can provide 
parameters related to tissue perfusion and permeability for examination of the tumor 
vasculature.  
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2.1.1 Dynamic contrast-enhanced ultrasound 
Contrast-enhanced ultrasound (CEU) imaging is based on the reception, analysis and 
display of acoustic signals produced by reflection or backscatter of sound (echo) with use of 
contrast agents. The most commonly used contrast agent are microbubbles that are gas-
liquid emulsions consisting of a gaseous core (e.g. perfluorocarbon, sulfur hexfluoride, or 
nitrogen) that is enclosed by a shell composed of biocompatible materials (albumin, 
galactose, lipids, polymers). The gaseous core of the microbubbles causes a very high 
echogenic response following insonification with ultrasound, resulting in high contrast-to-
tissue background ratio. Owing to their micron size (usually ranging in size between 1 and 4 
m in diameter), these microbubbles stay within the vascular compartment, and do not leak 
out into the extra-vascular space (Deshpande, Pysz et al. 2010). Thus, microbubbles are 
highly suitable for imaging angiogenic markers that are over expressed on tumor vascular 
endothelial cells (Deshpande, Needles et al. 2010). 
Following intravenous administration, microbubbles do not coalesce to form emboli, but 
dissolve leaving remnants that are easily metabolized or excreted. Further, biodistribution 
studies revealed that microbubbles have low circulation residence times as they are rapidly 
removed by the reticuloendothelial system (Perkins, Frier et al. 1997; Weskott 2008; 
Willmann, Cheng et al. 2008). To increase the circulation time of the microbubbles in serum, 
additional coatings, such as polyethylene glycol polymer arms are added onto the 
microbubble shell. Additionally these coatings help stabilize the microbubble by providing 
additional steric protection, preventing aggregation and help escape immune surveillance 
by the body (Klibanov 2009).  
To make ultrasound a molecular imaging tool, contrast microbubbles can be functionalized 
with ligands such as antibodies or peptides that bind molecular marker of interest with high 
affinity (Klibanov, Hughes et al. 1999). These binding ligands can either be coupled to the 
microbubbles using non-covalent attachment, or chemical conjugation (Klibanov 2005), or 
they can be integrated into the microbubble shell directly during the production process or 
after manufacturing (Pochon, Tardy et al. 2010; Pysz, Foygel et al. 2010). 
The huge benefit of using microbubbles is that the microcirculation can be detected. Since 
the nonlinear signals from microbubbles occur regardless of their motion and equally when 
they are stationary, CE US detects the capillary bed, which is by far the largest part of the 
microcirculation. Of course, its spatial resolution is limited, so that individual capillaries 
cannot be discerned, but the microbubble content gives rise to a signal ‘wash’ whose 
intensity is proportional to the microbubble concentration and thus to the blood volume in 
that portion of tissue (Figure 1).  
To estimate or measure perfusion, the essential tool is the transit or wash-in, wash-out 
curve, often referred to as the time-intensity curve (TIC) in which the time course of the 
transit of the microbubbles across a region of interest (ROI) is measured (Cosgrove and 
Lassau 2010). Two families of information are available from these TICs, those that depend 
on timing events, such as the arrival time and the time to peak enhancement, and those that 
depend on the amount of enhancement detected, such as the peak enhancement and the 
area under the TIC. These indices are rather more complex as they rely on a number of key 
assumptions. One is that the signal strength is proportional to the microbubble 
concentration (Blomley, Albrecht et al. 1997; Claassen, Seidel et al. 2001). Another 
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assumption is that all the non-linear signals in the ROI do emanate from the microbubbles, 
rather than from tissue.  
 
Fig. 1. Four images from a patient with pathologic proven rectal neuroendocrine tumor that 
is metastatic to the right lobe of the liver. (a) & (b) are conventional ultrasound images of the 
right lobe of the liver which demonstrates a well circumscribed, hypoechoic mass. (c) & (d) 
are contrast mode rapid ultrasound following injection of 3 x 10-8 microbubbles that are 
approximately 2.5 microns in size in a volume of 2.4mL. Panels (c) and (d) demonstrate 
different timepoints which demonstrate enhancement of the tumor fairly homogenously in 
(c), and in (d) washout of the tumor with enhancement of the hepatic venous system. 
(Figure from Dhyani & Samir et. al. unpublished data) 
The other way to generate boluses of contrast depends on the unique interaction between 
the imaging beam and the contrast agent: microbubbles are destroyed by higher intensity 
ultrasound which causes them to oscillate wildly and in complex patterns such that the gas 
escapes and the contrast effect is lost. The readiness with which this happens depends on 
the robustness of the shell, but for the commonly used clinical agent it is well within those 
licensed by regulatory agencies (usually a mechanical index (MI) of 1.9 is allowable). In a 
typical set-up, an infusion of microbubbles is used to achieve a steady blood concentration, 
and then a series of pulses at high MI is sent into the ROI before the system is switched back 
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to a low MI microbubble-specific mode for imaging (Wei, Jayaweera et al. 1998). The 
progressive inflow of the microbubbles in the cleared region can then be observed and the 
accumulation plotted. It takes the form of a rising exponential whose initial slope, , is 
related to the flow rate and whose maximum value, A, is related to the equilibrium 
concentration of the microbubbles, also known as the fractional vascular volume. The 
formula that is usually deployed is: 
 R = A (1-e (-t))  (1) 
though other approximations can be used (Lucidarme, Kono et al. 2003). An important 
difference between ultrasound and most other contrast agents should be stressed here: 
because of their relatively large size, microbubbles do not diffuse across the endothelium 
and into the interstitial space, unlike the ionic agents used for CT and MR. Advantages of 
this ‘destruction reperfusion’ method are its ready repeatability and the clean inflow 
function – there is no blurring effect from the upstream circulation as occurs following an iv 
bolus.  
The breast was one of the first tumors studies when contrast agents became available and 
striking differences between benign and malignant masses were reported (Kedar, Cosgrove 
et al. 1995). Not only was there more enhancement in malignancies but also the pattern was 
more chaotic. A rather crude attempt to evaluate transit times in the masses suggested that 
the cancers had earlier enhancement and retained the contrast for longer. Subsequent 
studies of breast masses have been less positive, with only poor enhancement and little 
differences between benign and malignant lesions as well as false positives where highly 
vascular fibroadenomas caused confusion (Rizzatto, Martegani et al. 2001; Jung, Jungius et 
al. 2005). In a more recent study of 50 consecutive patients with histological proof, QLab 
software was used to calculate features from TICs after bolus injections of SonoVue 
(Barnard, Leen et al. 2008). The area under the curve (AUC) and the peak enhancement were 
larger in malignant than benign lesions. 
The prostate has also been studied from early after the introduction of microbubbles, both to 
improve detection of cancers and to assess response to antiandrogen therapy (Eckersley, 
Sedelaar et al. 2002). Again, the techniques were crude, exploiting what was available. More 
recently, microbubble-specific modes and more durable microbubbles have become 
available, and reports of their usefulness in targeting biopsies promise to reduce the high 
proportion of negative biopsies (Frauscher, Klauser et al. 2003; Wink, Frauscher et al. 2008). 
A study found that DCE US was a useful method for evaluating the neovascularization of 
gastric carcinomas, and enhanced intensity (enhanced intensity is equal to peak intensity 
minus baseline intensity) had a strongly positive linear correlation with microvessel density 
(MVD) (Shiyan, Pintong et al. 2009). Another study found that DCE US was a valuable 
method for evaluating angiogenesis in colorectal tumors in vivo (Zhuang, Yang et al. 2011). 
This study also found that the area under the curve (AUC) had a positive linear correlation 
with MVD and could form a new index for assessing angiogenesis and the biological 
behavior of colorectal tumors. A recent study also found that the peak intensity and AUC 
reflected the MVD in ovarian tumors (Wang, Lv et al. 2011). 
In summary, DCE US is a powerful tool for studying neovascularization and the effect of 
anti-angiogenic therapy, with minimal morbidity. 
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2.1.2 CT perfusion 
CT perfusion (CTP) is a theoretical tool able to objectively quantify (with the use of 
mathematical models and dedicated software) the ‘real’ perfusion of tissues in that it only 
measures the density difference produced by the contribution of contrast material (and 
therefore of blood) to tissues. CTP is based on two indispensable technical requirements. 
 
Fig. 2. Effect of treatment on tumors in patients who completed entire combined treatment 
regimen, and surgery. (a) Endoscopic and pathological evaluation of rectal tumors. Surgical 
specimens showed grade II tumor regression in patients 1-5 and grade III in patients 6, by 
Mandard criteria. Endoscopic image (instead of surgical specimen) was taken for patients 6, 
3.5 weeks before surgery. BV, bevacizumab. (b) Representative functional CT images of 
blood perfusion before treatment (day 0), after bevacizumab (day 12) and after completion 
of treatment (day 104) in patient 5. (c) Tumor FDG uptake before treatment (pretreatment), 
12d after bevacizumab treatment and 6-7 weeks after completion of all neoadjuvant therapy 
(presurgery). Saggital projections of FDG-PET scans for patient 1 are shown. Tumor is 
outlined in box, posterior to the bladder. (Reprinted with permission from Nature Medicine, 
10(2), Willet et al. Direct evidence that the VEGF-specific antibody bevacizumab has 
antivascular effects in human rectal cancer., 145-7, Copyright 2004) 
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The first is the performance of repeated CT scans of the volume being analyzed (also known 
as dynamic, cine or perfusion scans). These need to be acquired before, during and after 
intravenous administration of iodinated contrast material to enable the study of density 
variations over time. The density measured by CT in the unit volume (voxel) is directly 
proportional to the quantity of contrast material present within it (Lee, Purdie et al. 2003). 
The contrast material contained within the tissue volume being studied is due to contrast 
material in vessels and contained in the extravascular/cellular space (or more simply, 
interstitial space) due to passive diffusion (Cenic, Nabavi et al. 2000). The second 
requirement is the selection of the arterial input. Placement of an ROI on an artery (arterial 
input) makes it possible to obtain a density/time curve, expressed in Hounsfield units (HU) 
per second (s), which is compared with the density/time curve of the tissues being studied, 
which is also obtained with placement of an ROI. Thanks to the comparison, the quantity of 
contrast material within vessels (vascular component) can be distinguished from contrast 
material within the interstitium (extravascular/cellular component). Lastly, with the use of a 
number of kinetic models, perfusion parameters can be calculated that quantify perfusion of 
the tissues being studied (Figure 2). 
Two-compartment (or Patlak) analysis sees the vascular compartment and the 
extravascular/cellular compartment as distinct, and quantifies exchange between them 
(Patlak, Blasberg et al. 1983). It provides an estimate of blood volume (BV) within the 
microvasculature and the extraction fraction (EF), also known as the transit constant (Ktrans), 
which is the sum of the flow within the microvasculature and capillary permeability. One-
compartment analysis (or slope method) enables the calculation of perfusion with short-
duration perfusion scans. Perfusion can be calculated as the ratio between the maximum 
slope of the density/time curve of tissue and the peak density reached by the artery selected 
as arterial input. The main advantage of this method is that it allows the calculation of 
perfusion with short-duration scans, in that the density/time curve of tissues reaches its 
maximum slope well before peak density. Short-duration scans are defined to include only 
the first pass of contrast material to avoid blood recirculation from interfering with 
perfusion quantification. In addition, they offer the advantage of being able to be performed 
in conditions of breath-hold in critical regions, thus limiting the possibility of motion 
artifacts. Nonetheless, this kinetic model is by its nature highly sensitive to noise present in 
the acquired images in that images are analyzed in a ‘discontinuous’ manner. Perfusion is, 
in fact, calculated by using only four images: the baseline image, the image obtained at peak 
density of the artery and the two subsequent images that show the greatest differences in 
tissue density. The presence of noise in one of these images can invalidate perfusion 
quantification (Miles and Griffiths 2003). 
Deconvolution-based perfusion analysis applies a mathematical operation of deconvolution 
to compare the density/time curve obtained from the arterial input and from the tissue 
being studied to obtain a theoretical concentration curve (of contrast material in the tissue 
being studied/time), known as the residual impulse response function (IRF) (Bronikowski, 
Dawson et al. 1983). Using the first part of the concentration curve, it can reasonably be 
assumed that the contrast material lies solely within the vascular compartment. In this 
fashion, blood flow (BF), BV and mean transit time (MTT) of blood within the 
microvasculature can be calculated according to the central volume principle, whereby BF = 
BV/MTT. In reality, the contrast material is distributed in the vascular compartment only 
exclusively in the brain parenchyma (where the blood-brain barrier hinders it passage into 
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the extravascular/cellular component), in the testicle and in the retina. In all other organs, 
the contrast material spreads via capillaries into the interstitium. Nonetheless, most contrast 
material diffuses in the interstitium late, and the amount that diffuses during the first pass is 
small. It can therefore be theoretically assumed that the contrast material is only in the 
vascular compartment in all other parenchyma if only the early scans are used for perfusion 
analysis (within the first 45-60s from contrast administration), with a maximum error of 
15%(Purdie, Henderson et al. 2001). Using the last part of the curve and the St. Lawrence 
and Lee adiabatic approximation, passage of contrast material into the interstitium can be 
quantified, with inclusion in the perfusion analysis of the CT scan performed after the first 
phase (therefore known as the interstitial phase). Calculating the permeability surface area-
product (PS) is done according to the following equation: 
 PS = -BF [in(1-E)],  (2) 
where E is the fraction of contrast that leaks into the interstitium from the vascular space 
(EF) (Petralia, Preda et al. 2010). 
A study of 23 patients with colorectal adenocarcinoma found that tumor permeability 
surface-area product and blood volume correlate positively with MVD and may reflect the 
microvascularity of colorectal tumors (Goh, Halligan et al. 2008). A study in 6 patients with 
primary or locally advanced adenocarcinoma of the rectum found that after a single infusion 
of bevacizumab (a VEGF-specific antibody) there was a significant decrease in tumor blood 
flow (40-44%) and blood volume (16-39%), which was accompanied by a significant 
decreased in tumor MVD (Willett, Boucher et al. 2004). A study of 20 patients with 
resectable soft tissue sarcoma treated with neoadjuvant bevacizumab and radiotherapy 
found that the BV, BF and PS decreased by 62-72% (Yoon, Duda et al. 2010). A study in 
patients treated with antiangiogenic therapy for metastatic renal cell carcinoma found that 
the baseline perfusion parameters were higher in responders than in stable patients, and 
that after the first cycle of treatment there was a significant decrease in BF and BV in 
patients receiving antiangiogenic treatment. They concluded that perfusion parameters 
determined with DCE CT could help predict biological response to antiangiogenic drugs 
before beginning therapy and help detect an effect after a single cycle of treatment 
(Fournier, Oudard et al. 2010). A further study in patients with advanced lung 
adenocarcinoma found that BF, BV and permeability values were higher in responding 
patients than in the other patients, with a significant difference at second follow-up for BF, 
BV and permeability (Fraioli, Anzidei et al. 2011). A study in patients with advanced HCC 
treated with bevacizumab initially and then in combination with gemcitabine and 
oxaliplatin, found that there was a significant decrease in BF, BV, and PS and an increase in 
MTT from baseline. They also found that tumors with higher baseline MTT values 
correlated with favorable clinical outcome and had better 6 months progression-free 
survival. The baseline Ktrans of responders was significantly higher than that of 
nonresponders. They concluded that CTP was a more sensitive image biomarker for 
monitoring early antiangiogenic treatment effects as well as in predicting outcome at the 
end of treatment and progression-free survival as compared with RECIST and tumor 
density (Jiang, Kambadakone et al. 2011). Another study found that perfusion MDCT can 
detect focal blood changes even when the tumor is shrinking, possibly indicating early 
reversal of tumor responsiveness to antiangiogenic therapy (Sabir, Schor-Bardach et al. 
2008).  
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2.1.3 Dynamic contrast enhanced MRI 
Functional dynamic contrast enhanced MRI (DCE-MRI) relies on the “leaky” nature of 
angiogenic blood vessels associated with malignancy. DCE-MRI is the acquisition of serial 
images before, during, and after the administration of an intravenous contrast agent, which 
produces time series images that enable pixel-by-pixel analysis of contrast kinetics within 
the tumor. PK models provide a means of summarizing contrast enhancement data in terms 
of parameters that relate to underlying vascular anatomy and physiology. Commonly used 
PK models assume that the contrast agent resides in and exchanges between two 
compartments in the tumor: the vascular space and the extravascular-extracellular space 
(EES) (Tofts 1997; Tofts, Brix et al. 1999). The contrast agent enters the tumor through the 
vascular space by perfusion, and diffuses between the vascular space and the EES. The rates 
of diffusion from the vascular space to the EES are determined by the concentrations of 
contrast agent in plasma and EES and the size and permeability of the capillary-EES 
interface (Brix, Semmler et al. 1991; Furman-Haran, Margalit et al. 1996; Knopp, Weiss et al. 
1999; Tofts, Brix et al. 1999; Knopp, Giesel et al. 2001).  
 
Fig. 3. Axial MR images from a patient with known metastatic renal cell carcinoma metastatic 
to retroperitoneal lymph nodes. (a) Overlying T1 weighted post contrast images are 
parametric permeability (Ktrans) images derived from bolus injection of gadolinium DTPA 
mathematically derived from analysis schemes as described in section 2.1.3. Please note the 
increased permeability throughout the metastatic lymph node. (b) Parametric images 
representing the apparent diffusion coefficient (ADC) at approximately the same level. Please 
note the homogeneous decreased signal intensity on ADC maps throughout the metastatic 
lymph node. One week following sunitinib therapy, there is dramatically decreased 
permeability within the metastatic lymph node on the superimposed Ktrans map (c), and there 
is heterogeneously increased ADC within the metastatic lymph node (d), both of which 
correspond to physiologic response to therapy. Figure from Rosen et al (unpublished data).  
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The majority of DCE-MRI studies are performed with small molecule, FDA approved 
Gadolinium based contrast agents. By mapping the T1 relaxation constant parametrically, 
and dynamically “following” the distribution of the contrast agent through the tumor 
microvasculature utilizing volumetric T1 weighted imaging, one can model the permeability 
and other parameters that may serve as surrogate biomarkers of angiogenesis (Figure 3 and 
4). To do this, the change in tumor concentration with time is governed by the differential 
equation: 
  dCtumor/dt=KtransCp-kepCtumor  (3) 
where Ctumor and Cp are the concentration of the agent in the EES and plasma space, 
respectively, Ktrans is the transfer constant between the plasma and the EES, and Kep + 
Ktrans/ve, where ve is the fraction of tumor volume occupied by the EES. Thus the 
concentration of contrast agent within the tumor is determined by the blood plasma 
concentration curve and the two parameters, Ktrans, the transfer constant, and the EES 








Fig. 4. (a) Maps of Ktrans, a measure of blood-brain barrier permeability. (b) T1-weighted 
anatomic images after intravenous administration of a contrast agent (gadolinium-DTPA), 
demonstrating a region of bright signal corresponding to the recurrent brain tumor in the 
left frontal lobe. Note the reduction in Ktrans following Gd-DTPA injection and kinetic 
analysis, and the accompanying shrinkage of the mass after injection of Cediranib (VEGF 
inhibitor). Figure from Jennings et. al. (unpublished data).  
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In relating the shape of the enhancement curve obtained from dynamic MRI studies, Ktrans 
controls the height of the Ctumor curve and kep = Ktrans/ve controls the shape of the curve; the 
smaller kep, the more delayed the enhancement. Ktrans is a function of flow (perfusion) and 
permeability; the greater the flow and permeability, the greater the Ktrans (Choyke, Dwyer et 
al. 2003) (Figure 5).  
 
Fig. 5. T1-weighted MRI of mice with pseudocolorized VVF maps superimposed through 
the center of the tumor within the right flank for each treatment arm (rapamycin (a), 
sorafenib (b), and control (c)) at baseline and at the end of therapy. Note the heterogeneity of 
signal intensity and color spread throughout the cohorts at baseline, with marked decrease 
in vascularity in the rapamycin (a) and sorafenib (b) treated animals as compared to control 
(c). Of note, only 3 mice survived all 3 weeks of treatment within the rapamycin treated arm. 
VVF was quantified each week in each cohort and graphed (mean +/- SEM) (d). Note the 
parallel, rapid decrease in VVF in both the sorafenib and rapamycin treated cohorts as 
compared to control with a statistically significant decrease in VVF (p<0.001) at week 3 in 
both cohorts relative to control. Although there was a decrease in mean VVF in control mice, 
there was no statistically significant difference in VVF comparing week 3 to baseline 
measurements in control mice. Figure from Guimaraes et. al. (unpublished data). 
Utilizing this approach in humans suffering from breast cancer, Hulka et al demonstrated a 
sensitivity of 86% and specificity of 93% for the diagnosis of malignancy (Hulka, Smith et al. 
1995; Hulka, Edmister et al. 1997; Tofts, Brix et al. 1999). Knopp et al expanded on these 
results and were able to demonstrate, by correlative analysis with VEGF and CD31 analysis, 
significantly faster enhancement characteristics between histologic subtypes (invasive ductal 
carcinoma, invasive lobular carcinoma and ductal carcinoma in situ)(Knopp, Weiss et al. 
1999). Subsequently, various groups have demonstrated, in vivo, in animal models and 
clinical trials, statistically significant differences in permeability transfer constants following 
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the administration of angiogenesis inhibitors (Pham, Roberts et al. 1998; Morgan, Thomas et 
al. 2003). Morgan et al demonstrated a rapid reduction in enhancement within 26 to 33 
hours after the first dose of the VEGF inhibitor PTK 787/ZK 222584 in a liver metastasis 
from colorectal carcinoma. This substantial reduction in enhancement is evident across all 
dose groups on day 2, with a mean reduction in permeability transfer constant of 43% 
(Morgan, Thomas et al. 2003). 
Despite these sophisticated models and encouraging results, pharmacokinetics modeling 
has been utilized with varying success to calculate blood volume of fractional plasma 
volume, with reported values demonstrating a correlation coefficient of R^2 0.61, and most 
studies indicate high sensitivity (>90%), but wide variability in specificity, with published 
values as low as 30% (Piccoli 1997). This variability is demonstrated well in a study by Su et 
al who performed DCE MRI on 105 patients with breast cancer and correlated it to VEGF 
serum marker levels as well as microvascular density as assessed post CD31 staining. 
Although patients with increased VEGF demonstrated higher CD31 microvascular densities, 
no significant association between MRI parameters and these other surrogate markers was 
demonstrated (Su, Cheung et al. 2003). In a study of 38 patients with advanced 
hepatocellular carcinoma treated with sunitinib, the investigators found significant 
decreases in Ktrans and Kep to approximately half. Moreover, the extent of decrease in Ktrans in 
patients who experienced partial response/stable disease was significantly greater (two-fold 
on average) compared with patients with progressive disease or who died during the first 
two cycles of therapy (Zhu, Sahani et al. 2009).  
DCE-MRI, in summary, has exciting potential to study the early effects of anti-angiogenic 
therapy in various organ systems.  
2.1.4 Positron emission tomography 
PET has been used in some studies to assess tumor blood flow with H2 15O as a biological 
endpoint of response to antiangiogenic agents (Herbst, Mullani et al. 2002). The principal 
advantage of H2 15O is that it is a ‘freely diffusible’ tracer, meaning that its uptake by the 
tumor is not limited by vascular permeability. H2 15O PET has been used to measure blood 
flow in several tumor types, including breast (Beaney, Lammertsma et al. 1984) and brain 
tumors (Ito, Lammertsma et al. 1982). The first report of the use of PET to measure vascular 
pharmacodynamics in humans was part of a phase 1 dose-escalation study of the tumor 
vascular targeting agent combretastatin A4 phosphate (CA4P) (Anderson, Yap et al. 2003). 
H2 15O PET was used to measure tumor and normal tissue perfusion and blood volume, 
before and after the administration of CA4P. Significant reductions in tumor perfusion were 
measured 30 minutes after administration of CA4P. However, there are potential 
limitations. H2 15O has a short half-life (2 minutes) and therefore studies require an on-site 
cyclotron and a separate tracer synthesis for each injection. In small tumors, partial volume 
effects may be significant if the tumor size is less than twice the resolution of the scanner. 
Second, there is a phenomenon known as ‘spill over’ or ‘spill in’ of counts from surrounding 
structures with high blood flow, such as the heart and the aorta, or within areas of relatively 
high blood flow, such as the liver, therefore limiting the use of this technique in the lung, 
liver and mediastinum.  
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2.2 Steady state blood volume determinations of neovascular density 
2.2.1 Magnetic resonance imaging 
Ultrasmall super paramagnetic iron oxide (a.k.a. magnetic nanoparticle (MNP)) is a steady 
state blood pool agent that creates contrast through magnetic susceptibility variations 
proximal to the vascular network (Enochs, Harsh et al. 1999; Tropres, Grimault et al. 2001; 
Corot, Robert et al. 2006; Persigehl, Bieker et al. 2007), which results in changes in inherent 
and induced transverse relaxation times defined as T2 and T2*, respectively. Accurate 
evaluation of R2* (1/T2*) or R2 (1/T2) necessitate defining two or more points on the natural 
or induced transverse relaxation decay curve. Addition of contrast agent increases R2* 
(1/T2*) thus causing limits on sampling as the T2* is shortened. It can be shown that: 
  R2* or R2  log [Spost/Spre] (4) 
where, Spre and Spost are pre- and post-contrast MRI signal intensity (Brown and Giaccia 
1998). The change in transverse relaxation rate R2 (1/T2) and changes in effective 
transverse relaxation rate R2* (1/T2*) caused by the contrast agent are proportional to 
tumor blood volume (BV) fraction (Belliveau, Rosen et al. 1990; Dennie, Mandeville et al. 
1998; Ostergaard, Smith et al. 1998). Therefore, the capability of MNP to modulate the 
effective transverse relaxation rate, R2*, is exploited where the difference of R2* before and 
after administration of MNP will be useful in determining microvessel density (Hyodo, 
Chandramouli et al. 2009).  
Bremer et al first utilized intravital microscopy to determine whether a prototype magnetic 
nanoparticle (MION) agent truly had intravascular distribution in tumor microenvironment 
(Bremer, Mustafa et al. 2003). For these experiments a green fluorescent protein expressing 
9L tumor model was utilized, in which tumor microvasculature is clearly outlined against 
fluorescent tumor cells, even at very high spatial resolution, which demonstrated that 
MION selectively enhanced the vascularity without any significant leakage into tumor 
interstitium during time of observation (30 minutes). They also found that steady state 
measures of vascular volume fraction (VVF) with MRI allow a volumetric, in vivo, non-
invasive assay of microvascular density in experimental tumor models. 
Pancreatic adenocarcinoma xenograft lines were subcutaneously implanted into nude mice, 
which were then therapies targeted to 3 loci of the sonic hedgehog signaling pathway. MRI 
imaging was performed 1 week after therapy, pre and post injection of MION-47. Following 
treatment, tumors showed a significant decrease in VVF compared to controls (Guimaraes, 
Rakhlin et al. 2008). A study on fibrosarcoma-bearing nude mice which were injection with a 
thrombogenic vascular targeting agent (VTA) found that the R2* values were significantly 
reduced shortly after treatment initiation and concluded that USPIO-enhanced MR imaging 
enable early monitoring of antiangiogenic treatment of tumors (Persigehl, Bieker et al. 2007).  
A recently published study on rhabdomyosarcoma-bearing mice treated with bevacizumab 
or saline as control, found that multiecho R2* MR relaxometry allowed an early and 
quantitative assessment of tumor vascularization changes in response to an antiangiogenic 
treatment (Ring, Persigehl et al. 2011). Another study on renal cell carcinoma-bearing mice 
treated with rapamycin (mTOR inhibitor), sorafenib (VEGF inhibitor) or saline control, VVF 
correlated with MVD and that the VVF in all treatment arms differed from control and 
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declined weekly with treatment. They also reported that VVF changes with rapamycin were 
similar to high-dose sorafenib (Guimaraes, Ross et al. 2011). 
Although not FDA approved, MNP enhanced MRI measures allow for interrogation of 
altered tumor microvascular morphology, and may serve as a robust means of evaluating 
the microstructural microvascular changes associated with anti-angiogenic therapy in 
humans.  
2.3 Specific molecular markers of angiogenesis 
Advances in knowledge of tumor angiogenesis have resulted in the identification of several 
molecules in tumor angiogenic signaling. These molecules have been exploited for their use 
as targets for molecular imaging and quantification of tumor angiogenesis. Furthermore, 
discovery of these molecules has led to realization of the concept that tumor vessels can be 
selectively targeted for therapy. Non-invasive molecular imaging of tumor angiogenesis can 
allow for much easier diagnosis and better prognosis of cancer, as well as more accurate 
treatment monitoring, which will eventually lead to personalized molecular medicine.  
2.3.1 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is one of the key factors regulating angiogenesis. 
Most of the vasculogenic and angiogenic effects of VEGF are mediated through two 
endothelium-specific receptor tyrosine kinases, VEGF receptor 1 (VEGFR-1) and VEGF 
receptor 2 (VEGFR-2)(Millauer, Wizigmann-Voos et al. 1993). VEGFR-1 is critical for 
physiologic and developmental angiogenesis, and VEGFR-2 is the major mediator of the 
mitogenic, angiogenic, and permeability-enhancing effects of VEGF (Ferrara 2004). In the 
imaging studies reported to date, however, specificity for ether VEGFR-1 or VEGFR-2 has 
rarely been achieved, because most of the tracers are based on VEGFA isoforms, which bind 
to both VEGFRs. Because of a high level of VEGFR-1 expression, rodent kidneys can take up 
a significant amount of a VEGFA-based tracer, a fact that often makes the kidneys the dose-
limiting organ. Because VEGFR-2 is generally accepted to be more functionally important 
than VEGFR-1 in cancer progression, this limits the use of current techniques. 
Recently, in vivo CE US imaging of VEGF/VEGFR expression has been reported. In 2 
murine tumor models, microbubbles conjugated to anti-VEGFR-2 monoclonal antibodies 
were used to image VEGFR-2 expression (Willmann, Paulmurugan et al. 2008). The targeted 
microbubbles produced a significantly higher average signal intensity than control 
microbubbles, and the signal intensity was significantly lower when anti-VEGFR-2 
antibodies (blocking antibodies) were used, demonstrating target specificity. 
99mTc-labelled human VEGF121 (one of the homodimeric isoforms of VEGFRA) has been used 
as a molecular imaging marker of VEGFR expression in an orthotopic mouse model of 
mammary adenocarcinoma, and for the imaging of tumor vasculature before and after 
tumoricidal cyclophosphamide treatment (Blankenberg, Backer et al. 2006). [123I]VEGF165 has 
also been reported as a potential tumor marker (Cornelissen, Oltenfreiter et al. 2005), but 
despite the high receptor affinity of this tracer, biodistribution in melanoma tumor-bearing 
mice indicated poor tumor-to-background ratios, most likely due to the low metabolic 
stability (deiodination) of the compound. Nonetheless, biodistribution, safety, and absorbed 
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dose of [123I]VEGF165 was studied in patients with pancreatic carcinoma (Li, Peck-
Radosavljevic et al. 2004). Following IV administration, sequential images were recorded 
during the initial 30 minutes after injection. Although a majority of primary pancreatic 
tumors and their metastases were visualized by the [123I]VEGF165 scan, the organ with the 
highest absorbed dose was the thyroid, indicating severe deiodination of the probe. 
To target the VEGFR-2, Backer et al (Backer, Patel et al. 2006) used single chain VEGF 
(scVEGF) with an N-terminal cysteine-containing tag (Cys-tag), which can be used for site 
specific attachment of various agents (Backer, Levashova et al. 2008). The scVEGF-based 
family of probes has been validated to target the VEGF receptor in vitro and in vivo tumor 
angiogenesis (Blankenberg, Backer et al. 2006; Levashova, Backer et al. 2008) 
64Cu-labelled VEGF121 has been used for PET imaging of tumor angiogenesis and VEGFR 
expression (Cai, Chen et al. 2006). DOTA-VEGF121 (where DOTA denotes 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) exhibits nanomolar receptor affinity in vitro. 
In an animal model, microPET imaging revealed rapid, specific, and prominent uptake of 
[64Cu]DOTA-VEGF121 in highly vascularized small xenografts (high VEGFR-2 expression) 
but significantly lower and sporadic uptake in large tumors (low VEGFR-2 expression). 
Substantial tracer uptake in the kidneys was also observed, most likely due to the high 
VEGFR-1 expression in this organ. 
A VEGFR-2-specific PET tracer based on mutant VEGF121 has been recently developed 
(Wang, Cai et al. 2007). The D63AE64AE67A mutant of VEGF121 (VEGFDEE), compared with 
VEGF121 had an affinity for binding to VEGFR-1 that was 20-fold lower, without a significant 
reduction in VEGFR-2-binding affinity. 
HuMV833, a humanized mouse monoclonal anti-VEGF antibody was labeled with 124I for 
PET imaging of solid tumors in phase 1 trial cancer patients (Jayson, Zweit et al. 2002). 
Antibody distribution and clearance were markedly heterogeneous between and within 
patients and between and within individual tumors, suggesting that dose escalation design 
of phase 1 studies with antiangiogenic antibodies such as HuMV833 would be problematic.  
2.3.2 Integrins 
Integrins are a family of cell adhesion molecules consisting of two noncovalently bound 
transmembrane subunits ( and ) that pair to create heterodimers with distinct adhesive 
capabilities. Integrin 3 mediates the migration of endothelial cells through the basement 
membrane during blood-vessel formation (Josephs, Spicer et al. 2009). Imaging of integrin 
3 expression is promising for the assessment of angiogenesis, as integrin 3 is 
significantly up-regulated on endothelium during angiogenesis, but not an quiescent 
endothelium (Brooks, Clark et al. 1994). In addition, in healthy tissue, expression of integrin 
3 is highly restricted with significant amounts only observed in osteoclasts (van der Flier 
and Sonnenberg 2001). Integrin 3, which mediates the migration of endothelial cells 
through the basement membrane during blood-vessel formation, binds to peptides 
containing the amino-acid sequence arginine-glycine-aspartic acid (RGD) within the 
interstitial matrix (Haubner 2006). By labeling these peptides with 125I, 111In, 64Cu, 99mTc, 18F 
or fluorescence dyes, specific binding of imaging agents to integrin 3 in tumors has been 
demonstrated (Haubner, Wester et al. 1999; van Hagen, Breeman et al. 2000; Haubner, 
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Wester et al. 2001; Janssen, Oyen et al. 2002; Chen, Conti et al. 2004; Beer, Lorenzen et al. 
2008). 
Targeted ultrasound imaging of integrin 3 during tumor angiogenesis has been reported 
(Ellegala, Leong-Poi et al. 2003). In a rat model of human glioblastoma, CEU was performed 
with microbubbles coated with echistatin, an RGD-containing disintegrin, which binds 
specifically to integrin 3. The CEU signal was found to be highest at the periphery of 
tumors, where integrin expression was most prominent as indicated by 
immunohistochemistry, and correlated well with tumor microvascular blood volume.  
Gd3+-containing paramagnetic liposomes (300-350nm in diameter) have been used for MRI 
of integrin 3 expression (Sipkins, Cheresh et al. 1998). In that study, mMRI of squamous 
cell carcinomas in a rabbit model was achieved with LM609, a mouse antihuman integrin 
3 monoclonal antibody, as the targeting ligand. Peptidomimetic integrin 3 antagonist-
conjugated magnetic magnetic nanoparticles were tested in a Vx-2 squamous cell carcinoma 
model with the common clinical field strength of 1.5 T(Winter, Caruthers et al. 2003). The 
targeted nanoparticles increased the MR signal dramatically in the periphery of the tumor at 
2 hours after injection. Despite their relatively large size (~270nm in diameter), these 
nanoparticles penetrated into the leaky tumor neovasculature but did not migrate into the 
interstitum in appreciable amounts. In a later report, athymic nude mice bearing human 
melanoma tumors were successfully imaged with systemically injected integrin 3-
targeted paramagnetic nanoparticles (Schmieder, Winter et al. 2005). Very small regions 
(about 30mm3) of angiogenesis associated with nascent melanoma tumors were visualized 
by this technique, which may enable phenotyping and staging of early melanomas in 
clinical settings. 
Integrin 3-targeted ultrasmall SPIO nanoparticles were used with a 1.5T RI scanner for 
the noninvasive differenciation of tumors with large and small fractions of integrin 3–
positive tumor vessels (Zhang, Jugold et al. 2007). After injection of RGD peptide-
conjugated small SPIO nanoparticles, T2*-weighted MR images revealed the heterogeneous 
distribution of integrin –positive tumor vessels, as evidenced by an irregular signal intensity 
decrease. In contrast, the signal intensity decreased homogeneously in the control tumor, 
with predominantly small and uniformly distributed vessels. 
In recent years, many fluorescently labeled cyclic RGD peptides have been developed for 
near infrared fluorescence imaging like RGD-Cy7, RGD-Cy5.5, RGD-QD705 (Chen, Conti et 
al. 2004; Cai, Shin et al. 2006; Wu, Cai et al. 2006) and cyclic RGD coupled to IRDye 800CW-
labeled peptide which is even more shifted towards the infrared parts of the spectrum 
resulting in ideal fluorescent characteristics for in vivo use (Adams, Ke et al. 2007). Mulder 
et al (Mulder, Koole et al. 2006; Mulder, Castermans et al. 2009) recently described 
paramagnetic lipid-encapsulated quantum dots with RGD presented at the outside and a 
green fluorescent quantum dot at the inside of the micellar shell. These targeted particles are 
both suitable for fluorescence imaging as well as MRI, thus providing unique opportunities 
for the use of multimodality molecular imaging. 
Several groups have improved 3 integrin specificity, binding affinity, and possible 
targeted delivery of therapeutics, by coupling multiple RGD motifs on a backbone molecule 
(Kok, Schraa et al. 2002; Cheng, Wu et al. 2005; Mulder, Koole et al. 2006; Jin, Josserand et al. 
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2007; Mulder, Castermans et al. 2009). Although, many types of tumor cells are positive for 
3 integrin, RGD-modified proteins mainly localize at the tumor endothelium and not in 
the tumor itself (Schraa, Kok et al. 2002). 
The commercially available near infrared fluorescent (NIRF) probe IntegriSense (Visen 
Medical) consists of a small molecule nonpeptide 3 antangonist fused to the VivoTg-S680 
near infrared fluorophore. IntegriSense has a much higher specificity for 3 integrin 
compared to RGD-based probes. Unlike RGD-based probes, extravasation of IntegriSense 
does occur and the probe localizes at both the surface of 3 integrin positive endothelial 
cells and the surface 3 integrin positive tumor cells. Furthermore, IntegriSense is 
internalized by the 3 integrin positive tumor cells leading to a slower clearance of the 
probe from tumors compared to the surrounding tissues. A drawback of the slower 
clearance from the tumor is the practical upper limit on the possible frequency of repeated 
measurements (Kossodo, Pickarski et al. 2010). 
A dimeric RGD peptide E[c(RGDyK)]2 (abbreviated as FRGD2) has been labeled with 18F. A 
high accumulation of 18F-FRGD2 in integrin 3 –rich tumors was demonstrated with a 
high tumor/background ratio at late time points of imaging (Zhang, Xiong et al. 2006). A 
glycopeptides based on c(RGDyK) was later labeled with 18F and the resulting 18F-galacto-
RGD was found to be safely administered to patients and allowed detection of integrin-
positive tumors (Haubner, Weber et al. 2005). Despite the successful translation of 18F-
galacto-RGD into clinical trials however, several key issues remain to be resolved, such as 
tumor-targeting efficacy, pharmacokinetics, and the ability to quantify integrin 3 density 
in vivo. Indeed, other promising multimetric RDG peptides are being investigated and may 
give better localization than galacto-RGD (Cai, Niu et al. 2008) 
Etaracizumab, a humanized murine monoclonal antibody against human integrin 3 has 
been conjugated with a chelating agent DOTA and labeled with 64Cu. The resulting 
[64Cu]DOTA-etaracizumab correlated well with integrin 3 in tumor xenografts via PET 
imaging (Cai, Wu et al. 2006). MicroPET studies revealed avid [64Cu]DOTA-etaracizumab 
uptake in integrin 3 -positive tumors. The receptor specificity of [64Cu]DOTA-
etaracizumab was confirmed by effective blocking of tumor uptake with co-administration 
of non-radioactive etaracizumab. 
A nanoparticle-based probe has been used for both MRI and optical imaging of integrin 
3. MRI-detectable and fluorescent liposomes carrying RGD peptides were evaluated for 
in vivo tumor imaging (Mulder, Strijkers et al. 2005). Both RGD-conjugated liposomes and 
RAD ( a control peptide that does not bind to integrin 3)-conjugated liposomes provided 
enhanced T1-weighted MR contrast. Ex vivo fluorescence microscopy revealed that RGD-
conjugated liposomes were specifically associated with the activated tumor endothelium, 
whereas RAD-conjugated liposomes were located in the extravascular compartment. 
A quantum dot (QD)-based probe for NIRF imaging and PET of integrin 3 has been 
developed (Cai, Chen et al. 2007). QD surface modification with RGD peptides allowed for 
integrin 3 targeting, and DTA conjugation enabled PET after 64Cu labeling. It was found 
that the majority of the probe in the tumor was within the vasculature, as evidenced by 
excellent overlay of the QD fluorescence signal and vasculature integrin 3 staining. This 
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dual-modality (PET/NIRF imaging) probe can confer sufficient tumor contrast at a 
concentration much lower than that required for in vivo NIRF imaging, significantly 
reduces the potential toxicity of cadmium-based QDs, and may hasten the future translation 
of QD-based imaging agents to clinical and biomedical applications. 
2.3.3 Transforming growth factor  
Transforming growth factor  (TGF-) signaling plays a role in several biological processes, 
including embryonic development, carcinogenesis, wound healing, and angiogenesis 
(Bernabeu, Lopez-Novoa et al. 2009). In normal cells, the TGF- pathway restricts cell 
growth, differentiation and cell death. In contrast, in malignant cells, various components of 
the TGF- signaling pathway become mutated thereby exploiting the ability of TGF- to 
modulate growth promoting processes, including cell invasion and angiogenesis. TGF- 
signaling is mediated by TGF- binding to TGF- receptors, of which, there are three classes: 
Type I and II are heterodimeric receptor whereas type III are homodimeric receptors . 
CD105, also known as endoglin, is a TGF- type III receptor that has been shown to 
participate in signaling angiogenesis. Endoglin is predominantly expressed on proliferating 
endothelial cells (Fonsatti, Altomonte et al. 2003), and inhibition of its expression has been 
shown to restore the growth suppressing signals of the TGF- signaling pathway (Ma, 
Labinaz et al. 2000). Thus, endoglin is an attractive molecular target of angiogenesis since it 
is over-expressed on tumor-associated endothelium (Bernabeu, Lopez-Novoa et al. 2009). 
Avidin (Av) was incorporated into the shell of perfluorocarbon-exposed sonicated dextrose 
albumin micobubbles (Av-MBs) to anchor biotinylated monoclonal antibodies (mAbs) 
(Korpanty, Grayburn et al. 2005). A rat anti-mouse CD105 mAb (MJ7/18) and an isotype-
matched control mAb were investigated for biotinylation, microbubbles incorporation, and 
cellular studies. It was found that MJ7/18-conjugated microbubbles bound specifically to 
endothelial cells but not fibroblasts, while the control mAb-conjugated Av-MBs did not 
exhibit CD105-specific targeting. After demonstrating the proof-of-principle, a follow-up 
study was carried out to follow the vascular response of therapy in mouse models of 
subcutaneous and orthotopic pancreatic adenocarcinoma (Korpanty, Carbon et al. 2007). For 
comprehensive investigation of angiogenesis in tumor-bearing mice treated with anti-VEGF 
mAbs and/or gemcitabine (a nucleoside analog with known activity against pancreatic 
adenocarcinoma), the localization of microbubbles targeting CD105, VEGFR-2, or VEGF-
activated blood vessels 9the VEGF-VEGFR complex) was monitored by ultrasound (Di 
Marco, Di Cicilia et al. 2010). In the subcutaneous model, receptor-targeted microbubbles 
gave significantly better enhancement of tumor vasculature than the non-targeted or control 
mAbs-conjugated microbubbles. In addition, video intensity from targeted microbubbles 
correlated with the level of target expression (CD105, VEGFR-2, or the VEGF-VEGFR 
complex), as well as with MVD in tumors under either anti-angiogenesis or cytotoxic 
therapy. 
One study investigated the applicability of a human umbilical vein endothelial cell 
(HUVEC)-based in vitro model to mimic physiological and angiogenic vasculature (Vag, 
Schramm et al. 2009). High fluorescence signal was observed in proliferating HUVECs due 
to CD105 expression. 
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Molecular MRI of CD105 expression in tumor-bearing rats was achieved with Gd-DTPA-
containing stabilized liposomes (Gd-SLs) (Zhang, Feng et al. 2009). A series of targeted and 
non-targeted MRI contrast agents were compared in glioma-bearing rats: Gd-DTPA, Gd-
SLs, Gd-SLs conjugated to anti-CD105 mAbs (CD105-Gd-SLs), and Gd-SLs conjugated to 
control mAbs (IgG-Gd-SLs). Serial T1-weighted MRI before and after contrast agent 
administration revealed that the area with enhanced MRI contrast was restricted for CD105-
Gd-SLs but not for the other three groups. In addition, the degree of contrast enhancement 
over time also varied between different groups. For example, Gd-DTPA gave an early 
contrast enhancement which peaked at 30 minutes and declined to baseline values at 60 
minutes, while the signal intensity for CD105-Gd-SLs continued to increase over a period of 
120 minutes. The signal intensity of IgG-Gd-SLs and Gd-SLs both peaked at 60 minutes 
followed by a decline, yet the rate of decrease was quite different. Ex vivo histology further 
revealed that the enhancement in the CD105-Gd-SLs group resulted mainly from new 
microvessels. However, both mature microvessels and new microvasculature were 
responsible for contrast enhancement in the other three groups.  
A study investigated an 111In-labeled anti-CD105 mAb (MJ7/18) and compared its 
neovascular binding, tumor accumulation, and in vivo behavior in an isotype-matched 
control mAb (Bredlow, Lewin et al 2000) In a B16 melanoma model, the tumors in animals 
receiving 111In-labelled MJ7/18 were more easily identified than animals receiving the 
radiolabeled control mAb. However, the tumor contrast was only modest. Ex vivo 
autoradiography and histology experiments of the tumor sections corroborated the different 
patterns of in vivo tumoral accumulation for the two antibodies. MJ7/18 exhibited intense 
activity in the peripheral region of the tumor, where the highest concentration of vessels 
was found, and much lower activity in the tumor center. On the other hand, little 
accumulation of activity could be found in tumors of mice that had been injected with 111In-
labeled control mAb.  
Another study tested a 125I-labeled anti-CD105 mAb (MAEND3) in a canine mammary 
carcinoma model (Fonsatti, Jekunen et al. 2000). After demonstrating differential expression 
of CD105 on human breast cancer and endothelial cells, two dogs with spontaneous 
mammary tumors were intravenously injected with 125I-laveled MAEND3 and imaged eight 
hours later. Rapid and intense uptake of the radiolabeled mAb with excellent tumor-to-
background ratio was observed in the tumor areas of both dogs, which were confirmed as 
ductal mammary adenocarcinoma after surgical excision ten days later. Another study also 
explored the use of 125I-labeled anti-CD105 mAb for radioimmunotherapy applications in 
mouse tumor models (Tabata, Kondo et al. 1999). Significant growth suppression of the 
tumors was observed while a 125I-labeled control mAb did not show any significant anti-
tumor efficacy.  
A 99mTc-labelled anti-CD105 mAb (E9) was investigated in freshly excised kidneys from 
renal carcinoma patients (Costello, Li et al. 2004). After perfusion of 99mTc-E9 through the 
renal artery, immunoscintigraphy revealed the presence of well-defined radioactive hot 
spots, which matched the positions of the tumors as identified by pre-surgery MRI and 
subsequent histology. Gamma-counting revealed that the median values of radioactivity 
uptake per gram of wet weight were > 10 fold higher in the tumors than in normal kidney 
tissues. Not only was CD105 specificity of the tracer confirmed by blocking studies, 
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immunoscintigraphy with 99mTc-E9 was also able to identify tumors that were not detected 
during pre-surgery MRI. 
2.3.4 Matrix metalloprotienases 
Expression of matrix metalloproteinases (MMPs) is associated with the removal of the 
extracellular matrix (ECM) barrier to allow cancer cells ad endothelial cells to invade the 
basement membrane. A number of MMPs are also specifically involved in angiogenesis, 
including MMPs 1, 2, 3, 9, and 14 (Stollman, Ruers et al. 2009).  
One approach for monitoring MMP activity in tumor-bearing animal models is the use of 
‘smart’ fluorescence probes that are bound to a synthetic graft copolymer consisting of a 
cleavable backbone that can act as an MMP substrate. When placed in close proximity, these 
polymeric fluorochromes quench each other and are not detectable. On enzymatic cleavage 
of the backbone by MMPs, the fluorochromes are spatially dissociated and begin to 
fluoresce (Bremer, Bredow et al. 2001) 
3. Clinical relevance of the finding 
The development of anti-angiogenic agents has been rapid to date. Although demonstrating 
provocative physiologic effects, the results to date have not demonstrated any significant 
improvements in patient outcome. This may be a result of various factors including a better 
understanding of the timing associated with the greatest changes occurring physiologically 
or morphologically within the microvasculature, a better understanding of whether the 
hypothesis of vascular normalization (Jain 2001; Jain 2005) (Goel, Duda et al. 2011) has 
bearing and may be a window into the introduction of other targeted cytotoxic agents, and 
improved, translatable targeted molecular imaging approaches to interrogating the tumor 
microenvironment. As these methods evolve in parallel, one may see come to fruition a true 
clinical benefit to the outstanding insight proposed from Dr. Folkman’s (Folkman 1971) 
seminal article many years ago.  
4. View to the future 
In order to bridge this gap in understanding the effects of angiogenesis, significant 
improvements and developments will have to occur within the following areas: 1) 
improvements in quality assurance and quality control associated with the physiologic 
measurements on interrogate the permeability, blood flow, and blood volume values that 
MRI, CT and PET; 2) improvements in targeted, molecular imaging approaches that may 
reflect the molecular changes that are occurring following administration of extant and 
novel anti-angiogenic or vascular disrupting agents, and lastly; 3) utilizing both of these 
approaches to better investigate and have a more comprehensive understanding of the 
validity and regulation of vascular normalization as a hypothesis for improved 
chemotherapeutic delivery is crucial.  
Perfusion imaging with MRI, CT or PET provides a unique window into the vascular 
morphology and physiologic changes associated with agents that disrupt the tumor 
microenvironment or microvasculature. As we have noted in this chapter thus far, these 
have had a profound impact on the initial evaluation of agents that target the tumor 
microvasculature. If performed with proper quality assurance/quality control, and critical 
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understanding of baseline variance, measures will allow for a more robust understanding of 
the true effects of agents targeted to the tumor microvasculature. Although many studies 
have demonstrated that there is in general good concordance with preclinical data and with 
other angiogenesis biomarkers, and if studies are performed well, the observations gleaned 
from these studies might improve the biologic understanding of the mechanism of drug 
action, potential drug interactions, and the duration of effects, however, the high variance 
demonstrated in many of these studies (>20% in some instances), makes proper 
determination of biologic effect sometimes suspect. This fact becomes more important as we 
go forward trying to study the correlation of these physiologic changes with clinical 
outcomes and relevant serum biomarkers. 
MRI molecular imaging may play a role in improving some of these problems illustrated 
above. As noninvasive molecular imaging methods evolve, there will be an increasing 
possibility to personalization of therapy. For instance, imaging of MRI reporter-labeled stem 
cells or endothelial progenitor cells will provide new insights into their role in tumor 
angiogenesis, as these cell types have been implicated in tumor vascularization and 
potential poor response to antiangiogenic therapies (Monzani and La Porta 2008) (van der 
Schaft, Seftor et al. 2004). Exciting developments have been made in identification of tumor 
vascular specific receptors, which opens up possibilities for imaging but also monitoring 
using nanodevices the delivery of therapeutic agents, or gene delivery. Likewise, similar 
advances have been made in siRNA technology, where image-guided delivery to tumor 
microvasculature, visualization of this delivery via liposome technology or other 
nanocarriers, and detection of a therapeutic response are well within the realm of current 
imaging capabilities (Pathak, Penet et al. 2010). Yet, these technologies to this point remain 
preclinical and successful translation to the clinic remains a hurdle.  
With all of the advances in imaging technology demonstrating effects and possible benefits 
of antiangiogenic therapy, the future of this kind of work remains unclear. One concept that 
has come to the fore and deserves mention is that of vascular normalization. A concept 
introduced by Rakesh Jain (Izumi, Xu et al. 2002), which describes the morphologic and 
physiologic changes that occur to tumor microvasculature accompanying anti-angiogenic 
therapy. This factor may be key in modulating the proangiogenic and anti-angiogenic forces 
ongoing in maintenance of the tumor microenvironment in addition to providing key 
insights into potential temporal windows for the introduction of cytotoxic agents. These 
questions remain the key to further improvements in the delivery of chemotherapeutic 
agents. “As a result, the presence and timing of therapy-induced normalization must be 
carefully studied in a range of human tumors, and novel therapeutics are needed. This will 
in part be informed by preclinical work, and also by development and validation of 
noninvasive biomarkers that survey the normalization phenotype. Only then will treatment 
be applied in a rational and judicious fashion with the intent of maximizing therapeutic 
outcomes” (Goel, Duda et al. 2011). 
5. Take home message 
The studies and techniques described attest to the validity of these extant and novel imaging 
techniques to probe the microstructural and morphologic microvascular changes that occur 
both as a result of tumor angiogenesis, and more importantly, soon after the delivery of anti-
angiogenic therapy. These can be performed indirectly, by measuring hemodynamic 
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parameters associated and related to blood volume, permeability and blood flow through 
imaging. These measures have been indispensible in the rapid and noninvasive 
interrogation of the microvascular changes accompanying antiangiogenic therapy. As 
existing techniques (e.g. DCE-MRI, CT perfusion, DCE-US) become more refined and 
validated by multi-institutional trials, the associated biomarkers may play a more pro-active 
role in the personalized approach that oncology is likely to engender. Furthermore, with the 
recent development of novel hybrid MRI PET devices, the realization and translation of 
more novel, targeted imaging approaches that probe the altered signaling pathways 
associated with angiogenesis, may become a reality in humans.  
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